Elena Elimova, MD, discusses data from a HERIZON-GEA-01 PD-L1 subgroup analysis in HER2-positive gastroesophageal adenocarcinoma.
Back
Examining the Benefits of a Zanidatamab Combo in HER2+ Gastroesophageal Adenocarcinoma
Sun Young Rha, MD, PhD, and colleagues discuss the survival benefits of a zanidatamab-based combination over trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma, irrespective of PD-L1 status.
Examining the Benefits of a Zanidatamab Combo in HER2+ Gastroesophageal Adenocarcinoma
Episodes
All
All
Zanidatamab plus tislelizumab and chemotherapy improved PFS and OS in HER2-positive mGEA regardless of PD-L1 status by TAP score or CPS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5